These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32301833)

  • 41. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.
    Gao Q; Meijer MJ; Schlüter UG; van Hogezand RA; van der Zon JM; van den Berg M; van Duijn W; Lamers CB; Verspaget HW
    Inflamm Bowel Dis; 2007 Jun; 13(6):693-702. PubMed ID: 17243139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
    Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
    Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
    J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
    Löfberg R; Louis EV; Reinisch W; Robinson AM; Kron M; Camez A; Pollack PF
    Inflamm Bowel Dis; 2012 Jan; 18(1):1-9. PubMed ID: 21351211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
    Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
    Aliment Pharmacol Ther; 2019 Aug; 50(3):289-294. PubMed ID: 31267570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Ward MG; Warner B; Unsworth N; Chuah SW; Brownclarke C; Shieh S; Parkes M; Sanderson JD; Arkir Z; Reynolds J; Gibson PR; Irving PM
    Aliment Pharmacol Ther; 2017 Jul; 46(2):150-161. PubMed ID: 28481014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study.
    Bager CL; Willumsen N; Kehlet SN; Hansen HB; Bay-Jensen AC; Leeming DJ; Dragsbæk K; Neergaard JS; Christiansen C; Høgdall E; Karsdal M
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1348-55. PubMed ID: 27411352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
    R-Grau Mdel C; Chaparro M; Mesonero F; Barreiro-de Acosta M; Castro L; Castro M; Domènech E; Mancenido N; Pérez-Calle JL; Taxonera C; Barrio J; De Francisco R; Fernández-Salgado E; Luzón L; Merino O; Oltra L; Saro C; Bermejo F; García-Sánchez V; Ginard D; Gutiérrez A; Vera I; Antón R; Ber Y; Calvet X; Gisbert JP
    Dig Liver Dis; 2016 Jun; 48(6):613-9. PubMed ID: 26992847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents.
    Hata T; Mizushima T; Osawa H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Ikenaga M; Nakajima K; Yamamoto H; Murata K; Doki Y; Mori M
    Surg Today; 2017 Mar; 47(3):320-327. PubMed ID: 27372080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Effect of anti-TNFα Induction Therapy on the Nutritional Status and Dietary Intake in Inflammatory Bowel Disease.
    Csontos ÁA; Molnár A; Piri Z; Katona B; Dakó S; Pálfi E; Miheller P
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):49-56. PubMed ID: 27014753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Citrullinated and MMP-degraded vimentin is associated with chronic pulmonary diseases and genetic variants in PADI3/PADI4 and CFH in postmenopausal women.
    Bager CL; Blair JPM; Tang ME; Mortensen JH; Bay-Jensen AC; Frederiksen P; Leeming D; Christiansen C; Karsdal MA
    Sci Rep; 2023 Dec; 13(1):23039. PubMed ID: 38155185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
    Kósa F; Kunovszki P; Borsi A; Iliás Á; Palatka K; Szamosi T; Vincze Á; Molnár T; Lakatos PL
    Dig Liver Dis; 2020 Mar; 52(3):274-280. PubMed ID: 31669077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease.
    Gamo K; Okuzono Y; Yabuki M; Ochi T; Sugimura K; Sato Y; Sagara M; Hayashi H; Ishimura Y; Nishimoto Y; Murakawa Y; Shiokawa Z; Gotoh M; Miyazaki T; Ebisuno Y
    Inflamm Bowel Dis; 2018 May; 24(6):1251-1265. PubMed ID: 29669006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Bar-Yoseph H; Levhar N; Selinger L; Manor U; Yavzori M; Picard O; Fudim E; Kopylov U; Eliakim R; Ben-Horin S; Chowers Y; Ungar B
    Aliment Pharmacol Ther; 2018 Jan; 47(2):212-218. PubMed ID: 29124774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents.
    Herrera-deGuise C; Casellas F; Robles V; Navarro E; Borruel N
    J Gastroenterol Hepatol; 2015 Feb; 30(2):286-91. PubMed ID: 25302652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.